On June 1, 2017 Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the first patient was dosed in its Phase 2 trial of LN-145 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (Press release, Lion Biotechnologies, JUN 1, 2017, View Source;p=irol-newsArticle&ID=2278256 [SID1234519425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have dosed our first patient in this trial evaluating LN-145 for the treatment of head and neck cancer. While some patients benefit from the few options available for the treatment of metastatic squamous cell carcinoma of the head and neck, there remains an unmet medical need for those who progress through such therapies," said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Lion Biotechnologies. "With this important milestone, patient dosing is now ongoing in two of our three Lion sponsored Phase 2 programs. We look forward to reporting data from these trials."

LN-145 is an adoptive cell transfer (ACT) therapy that utilizes an autologous TIL manufacturing process as originally developed by the National Cancer Institute. This Phase 2, multicenter, single-arm, open-label interventional study will enroll up to 47 patients and will assess the safety and efficacy of LN-145 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

Additional information on this study is available at www.clinicaltrials.gov.

On June 1, 2017 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported that Tito Serafini, Ph.D., President, Chief Executive Officer, and Co-Founder, will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017 at 8:00 a.m. Eastern Time in New York, NY (Press release, Atreca, JUN 1, 2017, View Source [SID1234522952]). Dr. Serafini will provide an overview of Atreca’s technologies, programs and progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 1, 2017 Debiopharm International SA (Debiopharm – www.debiopharm.com), part of Debiopharm Group, a Swiss-based global biopharmaceutical company, reported the results from the phase I dose-escalation study evaluating the compound Debio 1347/CH5183284 (FGFR 1,2,3 selective inhibitor). The data will be presented at the 53rd American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting by Martin H. Voss, MD, Medical Oncology at the Memorial Sloan Kettering Cancer Center in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to have reached this milestone and to be able to see these very interesting and promising results presented at the upcoming ASCO (Free ASCO Whitepaper) meeting. Despite not reaching the MTD, we are confident to have reached the right dose for phase 2 – given the indicators of anti-tumor activity that we have seen", said Chris Freitag, VP Clinical Research & Development.

Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
TITLE DATE AND TIME N°

Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.

Sat, June 3, 1:15 – 1:27
#2500

About Debio 1347/CH5183284
Debio 1347/CH5183284, created by Chugai Pharmaceutical. Co., Ltd., is an orally available small molecule targeting FGFR 1, 2, 3 signaling pathways. Debiopharm International SA completed the dose escalation portion of the first-in-human phase I study. Debio 1347/CH5183284 had a manageable safety profile. Encouraging antitumor activity was seen in several tumor types, mainly in patients with FGFR2 or 3 gene alterations, including fusion events. Efficacy will be further explored in disease-specific and molecularly defined expansion cohort.

On May 31, 2017 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, and the Dana-­Farber Cancer Institute reported that they have entered into a collaborative research agreement to focus Atreca’s IRC technology on the active immune responses of cancer patients whose disease is responding well to immunotherapy and other treatments (Press release, Atreca, MAY 31, 2017, View Source [SID1234522953]). The research will apply Atreca’s Immune Repertoire Capture (IRC) technology, which identifies and generates sequences of functional, native antibodies and T cell receptors (TCRs) from active human immune responses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A team of scientists led by F. Stephen Hodi, M.D., Director of the Melanoma Center and Center for Immuno-­Oncology at Dana-­Farber Cancer Institute/Brigham and Women’s Cancer Center and Professor of Medicine at Harvard Medical School, will collaborate with Atreca to study how different immunotherapies generate an active immune response, to understand why only a subset of patients benefit from therapy, and to identify anti-­tumor antibodies generated in these responses. The study will focus on patients with melanoma, non-­small cell lung cancer (NSCLC), and renal cell cancer, with the potential to expand into other cancer types.

"We are excited to collaborate with the accomplished team at Atreca. Through this unique collaboration, we believe we can work together to accelerate the discovery and development of novel therapeutic agents and treatment paradigms with the potential to improve patient outcomes in diverse cancer indications," stated Dr. Hodi.

"It is a thrilling opportunity for us to partner with one of the world’s leading institutions advancing cancer treatment," said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-­Founder. "Previous peer-­reviewed findings have demonstrated that our IRC technology delivers valuable data from the active immune responses of patients. We believe the collaboration with Dana-­Farber, focused on generating such actionable data, will make an important contribution to our immuno-­ oncology therapeutics programs."

Atreca applies IRC to generate sequences of native antibodies and TCRs from cancer patients, patients with autoimmune disease, vaccinated subjects, and patients who resolve infections. Analyses of the resulting essentially unbiased and error-­free repertoires yield valuable insights, as well as potent antibodies targeting tumors, pathogens, and autoimmune epitopes.

On May 31, 2017 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s cancer, reported that its chief executive officer, George O. Elston, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 10:00 am EDT (Press release, 2X Oncology, MAY 31, 2017, View Source [SID1234526105]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2X presentation will be webcast live and archived for 90 days on the Company’s website under the ‘News’ tab.

Mr. Elston will be joined by other members of the executive team for a breakout session immediately after the presentation, and for one-on-one meetings throughout the conference. Please contact your Jefferies representative or Amy Raskopf to schedule a meeting with 2X.